ELYM Eliem Therapeutics Inc

Price (delayed)

$2.75

Market cap

$76.23M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.3

Enterprise value

-$16.53M

Highlights
ELYM's quick ratio has soared by 86% YoY
ELYM's debt is down by 27% year-on-year and by 24% since the previous quarter
Eliem Therapeutics's equity has decreased by 16% YoY

Key stats

What are the main financial stats of ELYM
Market
Shares outstanding
27.72M
Market cap
$76.23M
Enterprise value
-$16.53M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.7
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$35.12M
EBITDA
-$34.71M
Free cash flow
-$20.6M
Per share
EPS
-$1.3
Free cash flow per share
-$0.76
Book value per share
$3.9
Revenue per share
$0
TBVPS
$4.09
Balance sheet
Total assets
$110.47M
Total liabilities
$2.87M
Debt
$349,000
Equity
$107.6M
Working capital
$107.42M
Liquidity
Debt to equity
0
Current ratio
38.92
Quick ratio
37.7
Net debt/EBITDA
2.67
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-30.4%
Return on equity
-31.4%
Return on invested capital
-58.7%
Return on capital employed
-32.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ELYM stock price

How has the Eliem Therapeutics stock price performed over time
Intraday
-0.72%
1 week
0.73%
1 month
0%
1 year
-16.16%
YTD
1.85%
QTD
1.85%

Financial performance

How have Eliem Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$40.28M
Net income
-$35.12M
Gross margin
N/A
Net margin
N/A
ELYM's net income is up by 22% year-on-year and by 11% since the previous quarter
The operating income has grown by 11% YoY and by 10% from the previous quarter

Growth

What is Eliem Therapeutics's growth rate over time

Valuation

What is Eliem Therapeutics stock price valuation
P/E
N/A
P/B
0.7
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Eliem Therapeutics's EPS has increased by 24% YoY and by 12% from the previous quarter
Eliem Therapeutics's equity has decreased by 16% YoY

Efficiency

How efficient is Eliem Therapeutics business performance
ELYM's ROIC is down by 36% YoY and by 16% QoQ
The company's return on equity rose by 7% QoQ and by 2.8% YoY
The return on assets rose by 6% since the previous quarter

Dividends

What is ELYM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELYM.

Financial health

How did Eliem Therapeutics financials performed over time
ELYM's quick ratio has soared by 86% YoY
The current ratio has soared by 77% YoY
ELYM's debt is 100% smaller than its equity
ELYM's debt is down by 27% year-on-year and by 24% since the previous quarter
Eliem Therapeutics's equity has decreased by 16% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.